In patients with thyroid cancer, the thyroid can lose the capacity to concentrate iodine and become refractory to radioiodine therapy. In this video, Daniel Pryma, MD, considers the maximal tolerated dose of radioiodine in patients with advanced thyroid cancer, and describes the distinguishing features of true radioiodine-refractory disease.
Related Links
Published
September 23, 2015
Created by
BROADCASTMED